Akeso has recently completed of the first patient enrollment in the Phase 3 head to head randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed PD-1/CTLA-4 bispecific antibody,#cadonilimab！ prnewswire.com/news-releases/…

Akeso is pleased to announce the acceptance of its IND application by the NMP for #AK139, a #bispecificantibody targeting #IL4Rα and #ST2. AK139 is under investigation for a number of indications, including respiratory and skin diseases. prnewswire.com/news-releases/…

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy prnewswire.com/news-releases/…

🎉 Celebrating 13 Wonderful Years of Akeso Biopharma! 🎂 Looking ahead, we remain steadfast in doing what is right, working towards a brighter global dream 🌍

Akeso Voice took the spotlight! 🎵 #Akso13YearsAnniversary #TeamSpirit #CheersToTheFuture

#STATUSList Akeso's CEO Dr. Xia has been selected for the 2025 STATUS List by STAT ! Dr. Xia is the only executive from a company based in Asia to be featured. statnews.com/status-list/20…

#Ebdarokimab, a novel humanized monoclonal antibody targeting IL-12/IL-23, developed by #Akeso, has received marketing approval from NMPA for the treatment of moderate-to-severe #plaquepsoriasis in adult patients. prnewswire.com/news-releases/…

#TIME100Health Dr. Michelle Yu Xia, Founder and CEO of #AkesoBiopharma, has been named to TIME's 2025 100 Most Influential People in Health time.com/collections/ti…

Top Biotechs at ASCO: Michelle Xia on Building Akeso and Advancing Dual-Target Immunotherapy Take a look! #Akeso #innovation #cancercare youtube.com/watch?v=un_bbe…

In a recent firesidechat with Ned Pagliarulo, Led editor of BioPharma Dive , our CEO, Michelle Yu Xia, shared exciting updates beyond just #ivonescimab — #cadonilimab, the #CD47 monoclonal antibody #ligufalimab, and the#Trop2/ #Nectin4 #ADC#AK146D1). lnkd.in/ekgMyCkU

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer